1. Home
  2. OTLK vs HMH Comparison

OTLK vs HMH Comparison

Compare OTLK & HMH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Outlook Therapeutics Inc.

OTLK

Outlook Therapeutics Inc.

HOLD

Current Price

$0.52

Market Cap

249.6M

Sector

Health Care

ML Signal

HOLD

Logo HMH Holding Inc. Class A Common Stock

HMH

HMH Holding Inc. Class A Common Stock

HOLD

Current Price

$18.10

Market Cap

237.2M

ML Signal

HOLD

Company Overview

Basic Information
Metric
OTLK
HMH
Founded
2010
2021
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Oil and Gas Field Machinery
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
249.6M
237.2M
IPO Year
2016
2024

Fundamental Metrics

Financial Performance
Metric
OTLK
HMH
Price
$0.52
$18.10
Analyst Decision
Buy
Strong Buy
Analyst Count
4
7
Target Price
$5.03
★ $28.71
AVG Volume (30 Days)
★ 3.8M
171.8K
Earning Date
08-14-2026
11-04-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 55.91
N/A
EPS
N/A
★ 1.26
Revenue
★ $8,146,123.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$6,355.64
$18.81
P/E Ratio
★ N/A
$13.71
Revenue Growth
N/A
N/A
52 Week Low
$0.16
$16.51
52 Week High
$2.54
$22.34

Technical Indicators

Market Signals
Indicator
OTLK
HMH
Relative Strength Index (RSI) 40.37 48.56
Support Level $0.40 $16.87
Resistance Level $0.72 $20.16
Average True Range (ATR) 0.05 0.86
MACD 0.01 -0.01
Stochastic Oscillator 50.19 56.82

Price Performance

Historical Comparison
OTLK
HMH

About OTLK Outlook Therapeutics Inc.

Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.

About HMH HMH Holding Inc. Class A Common Stock

HMH Holding Inc is a provider of offshore and onshore drilling equipment and services in the United States and Norway. Its services include sales of projects and products including drilling equipment packages for newbuild or a reactivated drilling rig, and individual or grouped components of drilling and pressure control equipment. The company also offers aftermarket services including services and replacement parts on installed equipment and integrated digital solutions. The company sells equipment and services to drilling contractors; operators, including both oil and gas E&P companies and mining companies onshore and offshore; and manufacturers, consisting of shipyards.

Share on Social Networks: